Trial · NCT02285634

The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.

NCT02285634, Not applicable, Completed, Mayo Clinic; results first posted 2018-10-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial. Trials, record NCT02285634. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02285634

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.
NCT number: NCT02285634
Status: Completed
Phases: Not applicable
Enrollment: 68 participants, actual
Lead sponsor: Mayo Clinic
Conditions: Epistaxis, Blood Pressure
Interventions: Oxymetazoline 0.05%, Phenylephrine 0.25%, Lidocaine 1% plus epinephrine 1:100,000, Bacteriostatic 0.9% NaCL
First posted: 2014-11-07
Last updated: 2018-10-02
Results first posted: 2018-10-02
Limitations and caveats: The primary limitation was the small sample size as enrollment was markedly more difficult than anticipated.

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Mean Arterial Blood Pressure	baseline, 30 minutes	Change in mean arterial blood pressure from the baseline measurement
Secondary	Change in Systolic Blood Pressure	baseline, 30 minutes	Change from baseline in systolic blood pressure.
Secondary	Change in Diastolic Blood Pressure	baseline, 30 minutes	Change from baseline in diastolic blood pressure.
Secondary	Change in Heart Rate	baseline, 30 minutes	Change from baseline in heart rate.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in Mean Arterial Blood Pressure	baseline, 30 minutes	mmHg	MEAN
SECONDARY	Change in Systolic Blood Pressure	baseline, 30 minutes	mmHg	MEAN
SECONDARY	Change in Diastolic Blood Pressure	baseline, 30 minutes	mmHg	MEAN
SECONDARY	Change in Heart Rate	baseline, 30 minutes	beats/min	MEAN

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Mean Arterial Blood Pressure	Oxymetazoline 0.05%	5.1	Standard Deviation 6.8	mmHg
Change in Mean Arterial Blood Pressure	Phenylephrine 0.25%	6.4	Standard Deviation 5.8	mmHg
Change in Mean Arterial Blood Pressure	Lidocaine 1% Plus Epinephrine 1:100,000	4.6	Standard Deviation 8.0	mmHg
Change in Mean Arterial Blood Pressure	Bacteriostatic 0.9% NaCL	6.5	Standard Deviation 5.5	mmHg
Change in Systolic Blood Pressure	Oxymetazoline 0.05%	7.5	Standard Deviation 9.8	mmHg
Change in Systolic Blood Pressure	Phenylephrine 0.25%	8.2	Standard Deviation 7.2	mmHg
Change in Systolic Blood Pressure	Lidocaine 1% Plus Epinephrine 1:100,000	3.5	Standard Deviation 6.5	mmHg
Change in Systolic Blood Pressure	Bacteriostatic 0.9% NaCL	8.9	Standard Deviation 5.4	mmHg
Change in Diastolic Blood Pressure	Oxymetazoline 0.05%	5.7	Standard Deviation 7.7	mmHg
Change in Diastolic Blood Pressure	Phenylephrine 0.25%	7.9	Standard Deviation 6.8	mmHg

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Oxymetazoline 0.05%	15
Overall Study	STARTED	Phenylephrine 0.25%	20
Overall Study	STARTED	Lidocaine 1% Plus Epinephrine 1:100,000	15
Overall Study	STARTED	Bacteriostatic 0.9% Sodium Chloride (NaCL)	18
Overall Study	COMPLETED	Oxymetazoline 0.05%	15
Overall Study	COMPLETED	Phenylephrine 0.25%	20
Overall Study	COMPLETED	Lidocaine 1% Plus Epinephrine 1:100,000	11
Overall Study	COMPLETED	Bacteriostatic 0.9% Sodium Chloride (NaCL)	17
Overall Study	NOT COMPLETED	Oxymetazoline 0.05%	0
Overall Study	NOT COMPLETED	Phenylephrine 0.25%	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nasal Pain	General disorders	Oxymetazoline 0.05%	2	15	2
other	Nasal Pain	General disorders	Phenylephrine 0.25%	2	20	2
other	Nasal Pain	General disorders	Lidocaine 1% Plus Epinephrine 1:100,000	0	11	0
other	Nasal Pain	General disorders	Bacteriostatic 0.9% NaCL	0	17	0
other	Eye watering	Eye disorders	Oxymetazoline 0.05%	1	15	1
other	Eye watering	Eye disorders	Phenylephrine 0.25%	0	20	0
other	Eye watering	Eye disorders	Lidocaine 1% Plus Epinephrine 1:100,000	0	11	0
other	Eye watering	Eye disorders	Bacteriostatic 0.9% NaCL	0	17	0
other	Diziness	General disorders	Oxymetazoline 0.05%	0	15	0
other	Diziness	General disorders	Phenylephrine 0.25%	1	20	1

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Oxymetazoline 0.05%	0	15
Total, all-cause mortality	Phenylephrine 0.25%	0	20
Total, all-cause mortality	Lidocaine 1% Plus Epinephrine 1:100,000	0	11
Total, all-cause mortality	Bacteriostatic 0.9% NaCL	0	17
Total, other adverse events	Oxymetazoline 0.05%	4	15
Total, other adverse events	Phenylephrine 0.25%	3	20
Total, other adverse events	Lidocaine 1% Plus Epinephrine 1:100,000	0	11
Total, other adverse events	Bacteriostatic 0.9% NaCL	2	17
Total, serious adverse events	Oxymetazoline 0.05%	0	15
Total, serious adverse events	Phenylephrine 0.25%	0	20

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30195946	BACKGROUND

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
UL1TR000135	Mayo Clinic Center for Clinical and Translational Science (CCaTS)	KHOSLA, SUNDEEP	MAYO CLINIC ROCHESTER	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	2012 to 2015

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02285634

GET https://conductscience.org/api/trials/v1/NCT02285634/registered

API reference For AI assistants